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e scintigraphy with radiolabelled autologous leukocytes (WBCs) is considered the gold-standard technique for imaging in-
fections. Leukokit® is a commercially available, disposable, sterile kit for labelling WBCs ex vivo. In this kit, WBCs isolation fromred blood cells (RBCs) was performed using poly(O-2-hydroxyethyl)starch (HES) as the RBCs sedimentation agent. Due to its
poor availability, HES has been recently replaced by Gelofusine as the RBC sedimentation agent. e aim of this study was to
compare the labelling eciency and the diagnostic accuracy of WBCs labelled with Leukokit® with HES vs Leukokit® withGelofusine. WBCs were isolated using HES or Gelofusine for 45minutes and then puried from platelets (PLTs) and labelled with
1.1± 0.3GBq of freshly prepared 99mTc-HMPAO. e following parameters were evaluated: the number and type of recovered
WBCs, RBCs contamination, PLTs contamination, vitality of neutrophils, and chemotactic properties of neutrophils. Clinical
comparison was performed between 80 patients (33 males; age 67.5± 14.2) injected with 99mTc-HMPAO-WBCs, using HES as the
sedimentation agent, and 92 patients (38 males; age 68.2± 12.8) injected with 99mTc-HMPAO-WBCs using Gelofusine as the
sedimentation agent. Patients were aected by prosthetic joint infections, peripheral bone osteomyelitis, or vascular graft in-
fection. We compared radiolabelling eciency (LE), nal recovery yield (RY), and diagnostic outcome based on microbiology or
2-year follow-up. Results showed that HES provides the lowest RBCs and PLTs contamination, but Gelofusine provides the
highestWBC recovery. Both agents did not in¢uence the chemotactic properties ofWBCs, and no dierences were found in terms
of LE and RY. Sensitivity, specicity, and accuracy were also not signicantly dierent for WBCs labelled with both agents
(diagnostic accuracy 90.9%, CI 74.9–96.1 vs 98.3%, CI 90.8–100, for HES and Gelofusine, respectively). In conclusion,
Gelofusine can be considered a suitable alternative of HES for WBCs separation and labelling.
1. Introduction
e scintigraphy with radiolabelled autologous leukocytes
(WBCs) is considered the gold-standard technique for
imaging infections, reaching a sensitivity and specicity
between 95% and 100% according to site [1–3], even
though several other agents are currently being developed
for direct imaging of bacteria [4, 5]. WBCs are usually
radiolabelled with two radiopharmaceuticals: 99mTc-
hexamethylpropylene amine oxime (99mTc-HMPAO) or
111In-oxine, following the EANM guidelines [6, 7]. WBCs
isolation from whole blood is a key procedure to obtain a
pure and specic radiopharmaceutical and to perform
radiolabelled leukocyte scintigraphy. Leukokit® (GIPharma, Italy) is a commercially available, disposable,
sterile kit for labelling WBCs ex vivo. In this kit, poly(O-2-
hydroxyethyl)starch (HAES-steril 10%, HES) has been
routinely used as a sedimentation agent to remove
erythrocytes (RBCs) from WBCs [8–12]. However, HES is
no longer commercially available, and it was replaced in
Leukokit® with an alternative agent, Gelofusine (B. Braun,Germany).
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)e aim of the study is to test in vitro the suitability of
Gelofusine as an alternative to HES. )is was achieved
through the assessment of several parameters after eryth-
rocyte separation: the number and type of recovered WBCs;
RBCs contamination; platelets (PLTs) contamination; via-
bility of neutrophils; chemotactic properties of neutrophils.
After the evaluation of safety and efficacy of the new
sedimentation agent (Gelofusine) performed by the pro-
ducers of Leukokit® (GI Pharma, Italy), we aimed at eval-uating the performance of this “new Leukokit®” (initiallyproduced by GI Pharma, Italy, and now produced by
CellTech, Italy), as compared to the previous kit containing
HES (“old Leukokit®” produced by GI Pharma, Italy), forWBCs purification and labelling with 99mTc-HMPAO, as
requested by the Italian legislation.
)e second goal of the study consists in the complete
validation of the “new Leukokit®”, containing Gelofusine, ascompared to the previously commercialized kit, containing
HES, applying our standard operating procedure (SOP) for
the validation and annual revalidation of the WBCs puri-
fication and labelling procedure.
Secondly, the “new” and the “old” Leukokit® werecompared in terms of WBCs labelling efficiency, recovery
yield, and diagnostic accuracy in patients with suspected
infections.
2. Materials and Methods
2.1. WBC Isolation. For the in vitro study, WBCs were
isolated from the blood of 5 healthy volunteers. In brief,
30ml of blood was withdrawn from each subject with a
syringe containing 6ml of anticoagulant citrate dextrose
(ACD). )e blood was then divided in 3 Falcon-type tubes
(12ml each) containing 3ml of HES, Gelofusine, or 0.9%
NaCl solution, respectively. Gelofusine was provided at 4%
concentration of a clear, transparent, and slightly yellowish
sterile solution (catalogue no. 152117651, B. Braun, Ger-
many). After approximately 40minutes of sedimentation,
cell-rich plasma (CRP) was collected from each vial and an
aliquot was used for FACS analysis to evaluate the number of
WBCs, RBCs, and PLTs contaminations. Another aliquot
was used for the viability testing by the trypan blue exclusion
test. )e remaining CRP was then centrifuged on
Lymphoprep® for 10minutes at 1000 rpm to isolate gran-ulocytes. After the centrifugation, the supernatant was
discarded and the pellet was resuspended in 5ml of phos-
phate buffered saline (PBS). FACS analysis and viability test
were then repeated, and the rest was used to evaluate the
retention of the migrating capabilities of granulocytes.
2.2. Migration Assay for Granulocytes. Granulocytes mi-
gration was evaluated using a 24-well permeable support
with 5 μm pores (Corning®) placed in a 24 multiwell plate.In the upper chamber of each well were placed 105 gran-
ulocytes in 100 μl of RPMI, whereas the lower chamber of
each well contained 650 μl of RPMI supplemented with 10%
FBS. )e plate was then incubated overnight in an incubator
at 37°C and 5% CO2. )e day after, the upper portion of the
membrane contained in each well was cleaned to remove
residual granulocytes and then the membranes were rinsed
in Coomassie blue followed by distilled water. Each mem-
brane was cut from the support and placed on a microscopy
slide for counting.
2.3. Leukokit® Validation. )e SOP for the validation in-cludes the following quality control tests (QC):
(i) QC1 for the evaluation of hydrophobicity of 99mTc-
HMPAO
(ii) QC2 for the evaluation of clumps after WBCs
purification and labelling by visual inspection
(iii) QC3 to calculate the labelling efficiency (LE) and
labelling yield (LY) of WBCs
(iv) QC4 to evaluate the sterility of the final product
(v) QC5 to evaluate the apyrogenicity of the final
product
(vi) QC6 to evaluate the vitality of radiolabelled cells by
trypan blue exclusion test
(vii) QC7 to evaluate the percentage of spontaneous
release of 99mTc-HMPAO from labelled WBCs at
different time points
Leukokit® validation was performed in 6 patients whodonated 60ml of blood each (age 30–60), once given the
written informed consent. For each patient, 60ml of blood
was withdrawn in two syringes with 6ml of ACD each (30ml
and 30ml of blood).
)e first 36ml was used forWBCs labelling with the “old
Leukokit®” containing HES as the sedimentation agent; theother 36ml was used for WBCs labelling with the “new
Leukokit®” containing Gelofusine as the sedimentationagent.
)e whole procedure requires between 2 h 45min and
3 h 30min depending on the erythrocyte-sedimentation rate
(ESR) of the patient. Additional 4 h were necessary to
complete all quality controls.
2.4. Clinical Analysis. Clinical comparison was performed
between 80 patients (33 males; age 67.5± 14.2) injected with
99mTc-HMPAO-WBCs, labelled using HES as the sedi-
mentation agent, and 92 patients (38 males; age 68.2± 12.8)
injected with 99mTc-HMPAO-WBCs, labelled using Gelo-
fusine as the sedimentation agent. Patients were affected by
prosthetic joint infections, peripheral bone osteomyelitis, or
vascular graft infection, as reported in Table 1.
Several parameters were considered: the radiolabelling
efficiency (LE), final recovery yield (RY), and diagnostic
outcome based on microbiology or 2-year follow-up.
For each group of patients, diagnostic accuracy, sensi-
tivity, specificity, negative-predictive value (NPV), positive-
predictive value (PPV), and their confidence intervals (CI)
were calculated considering the number of patients as true
positive (TP), true negative (TN), false positive (FP), and
false negative (FN) based on the correspondence between
the WBC scan and microbiology or follow-up.
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2.5. Statistical Analysis. Comparisons of WBCs concentra-
tion, RBCs and PLTs contamination, and migration results
were performed using Student’s t-test for continuous vari-
ables after confirmation of normal distribution by the
Kolmogorov–Smirnov test. Results in patients were statis-
tically compared performing the Student’s t-test, if normally
distributed, otherwise performing the Mann–Whitney test.
All results were given as mean values± SD or SE, unless
otherwise indicated. Differences were considered significant
when p values were <0.05. All calculations were performed
using Prism 7 (GraphPad Software, La Jolla, CA, USA).
3. Results
3.1. WBC Isolation. Gelofusine showed the best results in
terms of number of recovered WBCs and granulocytes
isolated from the blood of five healthy volunteers compared
to HES and control (Figure 1 and Table 2). Differences are
not statistically significant. Significant differences were
observed whenWBCs were purified from blood without any
sedimentation agent, as expected, due to the low erythrocyte
sedimentation speed (p � 0.02 and p � 0.03 for WBCs
concentration (before), respectively, for HES and Gelofusine
vs control; p � 0.04 and p � 0.07 for GRs concentration
(before), respectively, for HES and Gelofusine vs control).
On the contrary, the use of HES gave slightly lower RBCs
and PLTs contamination (Figure 2). Differences are not
statistically significant, except for PLTs contamination after
GRs isolation between HES and control (p � 0.04).
3.2. Vitality of Granulocytes. High viability of isolated gran-
ulocytes was observed before and after purification, as revealed
by the trypan blue exclusion test (Table 3 and Figure 3).
No statistical differences were observed between samples
analyzed immediately after sedimentation (total leukocytes)
or after centrifugation over the Lymphoprep® gradient(granulocytes). )e same applies for samples sedimented
with HES or Gelofusine or control.
3.3. Granulocyte Migration Assay. Isolated granulocytes
retained their ability to migrate in response to attracting
stimuli, as revealed by migration assays performed in me-
diumwith or without 10% FBS (Figures 4 and 5).)ere was a
significant difference between groups with or without FBS
stimulation (p � 0.001, p � 0.007, and p � 0.0006 for HES,
Gelofusine, or control groups, respectively).
In addition, there was no significant difference between
cells prepared with HES or Gelofusine or without any
sedimentation agent as control.
3.4. Leukokit® Validation. )e main QCs that are reportedhere (and of interest for the comparison of Gelofusine vs
HES) are the labelling efficiency (LE), the labelling yield
(LY), the vitality of labelled cells using the trypan blue
exclusion test, and the spontaneous in vitro release of 99mTc-
HMPAO from labelled WBCs at different time points in-
cubated at 37°C (10′, 1 h, and 4 h).
)e CRP volume was different for each patient,
depending on ESR of each one (range 20–30ml).
)e average labelling efficiency (LE) was similar between
the two sedimentation agents: 72.3± 4.8% for HES and
72.5± 8.9% for Gelofusine; the labelling yield (LY) was
slightly better for HES (54.5± 4.1%) than Gelofusine
(52.7± 5.8%). Differences were not statistically significant
(Figure 6).
Finally, the release of 99mTc-HMPAO from labelled
WBCs was evaluated. Results showed a less release from cells
at 10minutes for Gelofusine (4.9± 1.7%) in comparison to
HES (5.4± 1.5%), showing similar results at 1 h and 4 h
(10.8± 0.8% vs 9.3± 0.4%, respectively, at 1 h and
20.9± 2.4% vs 20± 2.2%, respectively, at 4 h) (Figure 7). All
differences are not statistically significant.
3.5. Clinical Analysis. For the “new Leukokit®,” the LE andRY, calculated on 92 samples, were 71.4± 11.4% and
55.6± 9.4%, respectively, whereas for the “old Leukokit®”,the LE and RY, calculated on 80 samples, were 74.5± 9.6%
and 54.8± 10.4%, respectively. Both differences were not
statistically significant (t-test p � 0.06 and p � 0.57, re-
spectively, for LE and RY).
As far as the diagnostic performance of the two kits is
concerned, we were able to include only 58 patients for the
“new Leukokit®” and 44 patients for the “old Leukokit®”because of the availability of reliable microbiological results
or clinical data during the 2-year follow-up.
As shown in Table 1, there were no statistically signif-
icant differences between the two groups of patients either if
Table 1: Summary of clinical results of patients with WBCs prepared using HES-Leukokit® or Gelofusine-Leukokit®.
Accuracy (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
HES
Osteomyelitis (n � 8) 87.5 50 100 100 85.7
Hip prosthesis (n � 13) 84.6 100 83.3 33.3 100
Vascular grafts (n � 3) 100 100 100 100 100
Knee prosthesis (n � 20) 95 100 94.4 66.7 100
All (n � 44) 90.9 (74.9–96.1) 83.3 (22.3–95.7) 92.1 (78.1–98.3) 62.5 (18.4–90.1) 97.2 (81.3–99.3)
Gelofusine
Osteomyelitis (n � 16) 100 100 100 100 100
Hip prosthesis (n � 16) 93.8 66.7 100 100 92.9
Vascular grafts (n � 5) 100 100 100 100 100
Knee prosthesis (n � 21) 100 100 100 100 100
All (n � 58) 98.3 (90.8–100) 91.7 (61.5–99.8) 100 (92.3–100) 100 (71.5–100) 97.9 (88.7–99.9)
All values are expressed as percentage, and the confidence intervals are given in brackets.
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we consider them in all or by single pathology (Pearson’s
chi-square test).
4. Discussion
WBCs isolation and radiolabelling are critical steps to obtain
an available radiopharmaceutical with high purity and la-
belling eciency, suitable for WBCs scintigraphy [13–16].
e availability of a sterile device, Leukokit®, has absolutelyprovided an instrument to facilitate the whole procedure,
reducing time and assuring sterility as reported in the recent
guidelines published by EANM Committee [14]. e utility
and safety of Leukokit® were reported in several studies thatobtained high values of LE and RY comparable to our study
[3, 8–11, 17, 18]. ese studies used 99mTc-HMPAO-WBCs
with Leukokit®. Hence, Leukokit® has been used for WBClabelling also using other chelating agents for 99mTc [19] or
other isotopes such as 111In [20, 21], 18F-FDG [22, 23], and
64CuCl [24]. us, the use of Leukokit® plays a pivotal rolefor WBCs isolation and radiolabelling procedure in clinical
practice. Indeed, Gelofusine was chosen as an alternative to
HES as plasma expander within the Leukokit®. It is
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Figure 1: Recovery of total WBCs and granulocytes (GRs) when using HES, Gelofusine, or control (0.9% NaCl) before ((a)–(d)) and after
((e)–(h)) GR isolation (error bars SE).
Table 2: Values of recovered blood elements after erythrocyte sedimentation with HES, Gelofusine, or control (before). e analysis was
repeated after granulocyte purication by centrifugation.
HES Gelofusine Control
Before After Before After Before After
Mean WBCs (106) 29.9± 8.5 4.3± 1.0 32.0± 10.3 6.1± 2.1 4.2± 3.1 4.1± 3.2
Mean GRs (106) 19.1± 7.1 3.8± 1.0 20.8± 8.0 5.5± 2.0 1.6± 1.4 1.3± 1.0
Mean RBCs (106) 0.2± 0.04 0.1± 0.01 0.1± 0.04 0.1± 0.01 0.02± 0.02 0.05± 0.02
Mean PLTs (106) 1893.4± 251.3 9.7± 3.6 1450.3± 246.8 13.5± 2.7 304.5± 170.4 27.2± 6.3
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RBCs after sedimentation
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Figure 2: RBC and PLTcontamination when using HES, Gelofusine, or control (0.9% NaCl) before and after GR isolation (error bars SE).
Table 3: Viability of mixed leukocytes or puried granulocytes tested by the trypan blue exclusion test.
HES Gelofusine Control
Subject Leukocytes (%) Granulocytes (%) Leukocytes (%) Granulocytes (%) Leukocytes (%) Granulocytes (%)
A 99.8 99.2 99.9 99.4 98.8 98.5
B 99.2 99.1 99.7 99.5 99.6 99.3
C 99.4 99.5 99.4 99.2 99.5 99.5
D 99.3 99.6 99.9 99.3 99.6 99.8
E 99 99.5 99.1 99.8 99.2 99.4
A B C D E
H
ES
G
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e
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ro
l
Figure 3: Trypan blue exclusion test of WBCs showing very high cell viability after erythrocyte sedimentation with HES, Gelofusine, or
control solution. Each square represents a random eld from 5 dierent subjects (A, B, C, D, and E).
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commercially available at 4% concentration with amolecular
weight average of 26500Da.
In our study, HES and Gelofusine were compared in
vitro and in clinical practice after the introduction of
Gelofusine in the Leukokit®.From our results, Gelofusine allowed a better separation
of granulocytes from whole blood of healthy subjects as
compared to HES, with optimal cell vitality.
From data collected in patients, labelling eciency and
labelling yield were similar for the two kits, and diagnostic
accuracy, sensitivity, specicity, PPV, and NPV were also
not signicantly dierent for both sedimentation agents.
ese results are in agreement with data previously pub-
lished [15, 16], being the overall diagnostic accuracy of the
two tests equal to 98.3% and 90.9% (for Gelofusine and HES,
respectively). In this study, we included only patients with a
clearly dened diagnosis, mainly because of availability of
microbiological data obtained during surgery or more rarely
because of a 2-year follow-up without use of any antibiotic
therapy. is selection may be at risk of bias, but rather than
providing data in support of WBCs scan, we aimed at
comparing with the same methodology and same source of
bias two dierent groups of patients. When subdividing
patients for dierent pathologies, we noticed that the
number of patients with suspected vascular graft infection is
too few to draw any conclusion, but even if removed from
total, the overall results are the same with no statistical
dierence between WBCs scans in patients using “old
Leukokit®” and “new Leukokit®”. In particular, in kneeprosthesis, we found a sensitivity and specicity of 100% and
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Figure 4: Granulocyte migration assay performed using medium
with (grey bars) or without (black bars) 10% FBS (error bars SD).
Figure 5: Random eld of Transwell membrane from subject C.
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Figure 6: Graphic representation of labelling eciency and la-
belling yield with dierent kits (data are mean of 6 subjects± SD).
e vitality test showed the same result for both sedimentation
agents with a mean value± SD equal to 99.7± 0.4%.
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Figure 7: Graphic representation of the spontaneous in vitro re-
lease of 99mTc-HMPAO from labelled WBCs at dierent time
points (data are mean of 6 subjects± SD).
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94.4%, respectively, for the “old Leukokit®” and a sensitivityand specificity of 100% and 100%, respectively, for the “new
Leukokit®”. Similarly, in hip prosthesis, we found a sensi-tivity and specificity of 100% and 83.3%, respectively, for the
“old Leukokit®” and a sensitivity and specificity of 66.7%and 100%, respectively, for the “new Leukokit®”. )eseresults are well in agreement with those recently published in
two meta-analysis by Verberne et al. in which they report an
overall sensitivity and specificity for radiolabelled WBCs
scintigraphy in knee prosthesis of 88% and 77%, respectively
[15], and in hip prosthesis a sensitivity and specificity of 88%
and 92%, respectively [16], although in all mentioned studies
WBCs were labelled without the use of Leukokit®.A possible criticism to our work can be raised by the
consideration that we used blood of normal subjects for the
in vitro experiments and not from patients. Indeed, the low
ESR in normal subjects could have negatively influenced the
sedimentation of RBCs and the purification of WBCs from
RBCs and PLTs. However, the choice of using blood from
normal subjects was done on purpose for ethical reasons and
for evaluating the efficacy of Gelofusine and HES in the
worst situation (i.e., when ESR is very low).
5. Conclusion
Both HES and Gelofusine sedimentation agents allowed
reproducible separation of granulocytes from whole blood
with a high percentage of purity and vitality as required by
EANM guidelines.
In particular, Gelofusine can be considered a suitable
alternative of HES for WBCs separation and labelling,
yielding to high labelling efficiency, without cell damage and
high diagnostic accuracy.
Data Availability
)e data used to support the findings of this study are
available from the corresponding author upon request.
Conflicts of Interest
)e authors declare that there are no conflicts of interest
regarding the publication of this paper.
Acknowledgments
)e authors wish to acknowledge the Nuclear Medicine
Discovery Association for providing financial support to this
study.
References
[1] A. W. Glaudemans, N. Prandini, M. DI Girolamo et al.,
“Hybrid imaging of musculoskeletal infections,” Quarterly
Journal of Nuclear Medicine and Molecular Imaging, vol. 62,
no. 1, pp. 3–13, 2018.
[2] C. Malherbe, A. C. Dupont, S. Maia et al., “Estimation of the
added value of 99mTc-HMPAO labelled white blood cells
scintigraphy for the diagnosis of infectious foci,” Quarterly
Journal of Nuclear Medicine and Molecular Imaging, 2017.
[3] P. A. Erba, A. W. J. M. Glaudemans, N. C. Veltman et al.,
“Image acquisition and interpretation criteria for 99mTc-
HMPAO-labelled white blood cell scintigraphy: results of a
multicentre study,” European Journal of Nuclear Medicine and
Molecular Imaging, vol. 41, no. 4, pp. 615–623, 2014.
[4] S. Auletta, D. Baldoni,M. Varani et al., “Comparison of 99mTc-
UBI 29-41, 99mTc-Ciprofloxacin, 99mTc-Ciprofloxacin di-
thiocarbamate and 111In-biotin for targeting experimental
Staphylococcus aureus and Escherichia coli foreign-body in-
fections: an ex-vivo study,” Quarterly Journal of Nuclear
Medicine and Molecular Imaging, vol. 63, no. 1, 2017.
[5] T. Ebenhan, E. Lazzeri, and O. Gheysens, “Imaging of bac-
teria: is there any hope for the future based on past experi-
ence?,” Current Pharmaceutical Design, vol. 24, no. 7,
pp. 772–786, 2018.
[6] E. F. J. de Vries, M. Roca, F. Jamar, O. Israel, and A. Signore,
“Guidelines for the labelling of leucocytes with 99mTc-
HMPAO,” European Journal of Nuclear Medicine and Mo-
lecular Imaging, vol. 37, no. 4, pp. 842–848, 2010.
[7] M. Roca, E. F. J. de Vries, F. Jamar, O. Israel, and A. Signore,
“Guidelines for the labelling of leucocytes with 111In-oxine,”
European Journal of NuclearMedicine andMolecular Imaging,
vol. 37, no. 4, pp. 835–841, 2010.
[8] A. Signore, A. W. J. M. Glaudemans, G. Malviya et al.,
“Development and testing of a new disposable sterile device
for labelling white blood cells,” Quarterly Journal of Nuclear
Medicine and Molecular Imaging, vol. 56, no. 4, pp. 400–408,
2012.
[9] M. Rannou, B. Dekyndt, N. Lheureux, and J. Legrand,
“Leukokit® for the radiolabeling of leukocytes with 99mTc-
HMPAO: balance of 5 months of use,” European Journal of
Nuclear Medicine and Molecular Imaging, vol. 41, pp. S436–
S437, 2014.
[10] A. Kolindou, M. Papachristou, A. Velidaki et al., “Labelling
procedure of autologous leukocytes with 99mTc-HMPAO
using Leukokit: description of our hospital experience,” Eu-
ropean Journal of Nuclear Medicine and Molecular Imaging,
vol. 42, p. S458, 2015.
[11] P. Fernandez, H. de Clermont-Gallerande, F. Dauchy,
K. Massaloux, and M. Dupon, “Imagerie scintigraphique de
l’infection des prothe`ses de hanche et de genou,” Me´decine
Nucle´aire, vol. 37, no. 8, pp. 353–361, 2013.
[12] A. B. Dart, T. C. Mutter, C. A. Ruth, and S. P. Taback,
“Hydroxyethyl starch (HES) versus other fluid therapies:
effects on kidney function,” Cochrane Database of Systematic
Reviews, vol. 1, no. 7, article CD007594, 2010.
[13] A. Signore and A. W. J. M. Glaudemans, “)e molecular
imaging approach to image infections and inflammation by
nuclear medicine techniques,” Annals of Nuclear Medicine,
vol. 25, no. 10, pp. 681–700, 2011.
[14] A. Signore, F. Jamar, O. Israel, J. Buscombe, J. Martin-Comin,
and E. Lazzeri, “Clinical indications, image acquisition and
data interpretation for white blood cells and anti-granulocyte
monoclonal antibody scintigraphy: an EANM procedural
guideline,” European Journal of Nuclear Medicine and Mo-
lecular Imaging, vol. 45, no. 10, pp. 1816–1831, 2018.
[15] S. J. Verberne, R. J. A. Sonnega, O. P. P. Temmerman, and
P. G. Raijmakers, “What is the accuracy of nuclear imaging in
the assessment of periprosthetic knee infection? A meta-
analysis,” Clinical Orthopaedics and Related Research,
vol. 475, no. 5, pp. 1395–1410, 2017.
[16] S. J. Verberne, P. G. Raijmakers, and O. P. P. Temmerman,
“)e accuracy of imaging techniques in the assessment of
Contrast Media & Molecular Imaging 7
periprosthetic hip infection,” Journal of Bone and Joint Sur-
gery, vol. 98, no. 19, pp. 1638–1645, 2016.
[17] C. Maurel, R. de Lemps, J. Marti, M. Razzouk-Cadet, and
C. Grangeon, “Complete validation of the granulocytes
radiolabeling method using Leukokit with introduction of a
density gradient medium,” European Journal of Nuclear
Medicine and Molecular Imaging, vol. 43, p. S464, 2016.
[18] N. Lheureux, J.-F. Legrand, A. Mackowiak, F. Semah, and
D. Huglo, “E´valuation du Leukokit® face a` la me´thode nativede radiomarquage des leucocytes autologues : l’expe´rience
lilloise,” Me´decine Nucle´aire, vol. 37, no. 5, pp. 171-172, 2013.
[19] S. Auletta, V. Iodice, F. Galli, N. Lepareur, A. Devillers, and
A. Signore, “Study of binding kinetics and specificity of 99mTc-
SSS-Complex and 99mTc-HMPAO to blood cells,” Contrast
Media & Molecular Imaging, vol. 2018, Article ID 5603902,
6 pages, 2018.
[20] J. Meller, G. Ko¨ster, T. Liersch et al., “Chronic bacterial os-
teomyelitis: prospective comparison of 18F-FDG imaging with
a dual-head coincidence camera and 111In-labelled autologous
leucocyte scintigraphy,” European Journal of Nuclear Medi-
cine and Molecular Imaging, vol. 29, no. 1, pp. 53–60, 2002.
[21] R. Bar-Shalom, N. Yefremov, L. Guralnik et al., “SPECT/CT
using 67Ga and 111In-labeled leukocyte scintigraphy for di-
agnosis of infection,” Journal of Nuclear Medicine, vol. 47,
no. 4, pp. 587–594, 2006.
[22] S. Yılmaz, M. Ocak, S. Asa et al., “)e different distribution
patterns of FDG and FDG-labelledWBC in inflammatory and
infectious lesions,” European Journal of Nuclear Medicine and
Molecular Imaging, vol. 39, no. 10, pp. 1660-1661, 2012.
[23] L. A. Forstrom, W. L. Dunn, B. P. Mullan, J. C. Hung,
V. J. Lowe, and L.M.)orson, “Biodistribution and dosimetry
of [18F]fluorodeoxyglucose labelled leukocytes in normal
human subjects,” Nuclear Medicine Communications, vol. 23,
no. 8, pp. 721–725, 2002.
[24] A. Pala, M. Liberatore, P. D’Elia et al., “Labelling of gran-
ulocytes by phagocytic engulfment with 64Cu-labelled
chitosan-coated magnetic nanoparticles,” Molecular Imag-
ing and Biology, vol. 14, no. 5, pp. 593–598, 2012.
8 Contrast Media & Molecular Imaging
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
